Comparing CGRP monoclonal antibodies vs gepants? Learn how each class works, how they differ in use and timing, and what questions to bring to your clinician.
When people start researching CGRP-targeted therapies, the question of CGRP monoclonal antibodies vs gepants comes up fast. Both drug classes act on the calcitonin gene-related peptide pathway, and both have changed how migraine is treated. But they are built differently, work differently, and are used for different purposes. Understanding those distinctions helps you have a more informed conversation with your neurologist.
For background on what CGRP actually is and why it matters in migraine, see What Is CGRP.
Monoclonal antibodies are large proteins produced in laboratory conditions to bind very precisely to a specific target. In the context of migraine, CGRP monoclonal antibodies target either the CGRP molecule itself or its receptor, blocking the signaling cascade that contributes to migraine attacks.
Because they are large molecules, they cannot be absorbed through the digestive tract. They are administered by subcutaneous injection (self-administered at home, usually monthly or quarterly) or intravenous infusion (given in a clinical setting). The dosing intervals are long because antibodies persist in the body for weeks before being broken down.
Their primary role is prevention, meaning they are taken on a regular schedule to reduce how often migraines occur, not to stop an attack that is already in progress. A detailed look at the mechanism is in How CGRP Antibodies Work.
Key characteristics:
Only your clinician can determine whether a CGRP monoclonal antibody is appropriate for you, and they will weigh your diagnosis, frequency, prior treatment history, and insurance requirements before prescribing.
Gepants are small-molecule drugs, which means they are chemically synthesized rather than grown as proteins. Small-molecule size allows them to be taken orally as tablets or orally disintegrating tablets. They work by blocking the CGRP receptor, preventing CGRP from binding and triggering its downstream effects.
Unlike the antibodies, gepants are cleared from the body relatively quickly. Most are designed to act within a couple of hours, making them useful for stopping an attack that has already started. Some gepants have also been approved for preventive use, taken on a regular schedule regardless of whether a migraine is occurring.
For a deeper look at how this class specifically works, see Gepants and Migraine Explained.
Key characteristics:
| Feature | CGRP Monoclonal Antibodies | Gepants |
|---|---|---|
| Molecule type | Large biological protein | Small chemical molecule |
| Route | Injection or IV infusion | Oral tablet |
| Primary use | Prevention | Acute treatment (some also preventive) |
| Dosing frequency | Monthly or quarterly | As needed, or daily/every other day |
| Onset of effect | Weeks to months for full benefit | Hours (acute use) |
| Duration in body | Weeks | Hours to a day |
| Risk of MOH | Not associated | Low (lower than triptans) |
| Administration setting | Home (auto-injector) or clinic (infusion) | Home |
MOH = medication overuse headache. If you want to understand that risk factor in more detail, Medication Overuse Headache covers how it develops and what to watch for.
Both classes can be used preventively, but CGRP monoclonal antibodies were specifically designed for this purpose from the start. They are typically considered for people with episodic migraine at higher frequency (often 4 or more migraine days per month) or chronic migraine (15 or more headache days per month, with 8 or more meeting migraine criteria for at least 3 months).
Some gepants have received regulatory approval for episodic migraine prevention at lower doses taken on a regular schedule. Whether that approach is appropriate versus starting a monoclonal antibody depends on factors your clinician will assess, including prior treatment history, how often you need acute treatment, and how well you tolerate each route of administration.
Gepants fill a role that CGRP monoclonal antibodies simply cannot: stopping an attack in progress. Because the antibodies work over weeks and are dosed months apart, they have no meaningful effect on a migraine that started an hour ago. Gepants, taken at the onset of an attack, can reduce pain and associated symptoms within a few hours.
This is also why some clinicians use both approaches simultaneously. A monoclonal antibody for background prevention, paired with a gepant for breakthrough attacks, is a pattern that appears in clinical practice. Your clinician makes that combination decision based on your full picture.
One practical advantage of gepants over older acute treatments like triptans and NSAIDs is their apparent lower risk of contributing to medication overuse headache (MOH). MOH develops when acute treatments are used too frequently, typically more than 10 to 15 days per month depending on the drug class, and paradoxically causes more frequent headache. While gepants appear less likely to trigger this cycle, the frequency of acute treatment still matters and is something worth tracking carefully.
Whether you are already on one of these therapies or considering starting, the data that matters most is:
The Chronic or Episodic Migraine tool can help you figure out which category your current pattern falls into, which is directly relevant to which class of therapy your clinician might consider. The Migraine Reduction Calculator lets you quantify your response if you are already on a preventive.
If you are on a CGRP monoclonal antibody and approaching a prior authorization renewal, consistent tracking data is what makes that packet strong. See CGRP Prior Authorization and Renewal for what insurers typically want to see.
No article can answer these for you. Your clinician knows your history, your other medications, and your insurance situation, and they are the only one who can start, stop, or change any treatment.
Logging your migraine days, acute medication use, and symptom patterns in the app converts the information in this article into the concrete before-and-after data your clinician and insurer actually need, whether that is for a new prescription, a dose adjustment, or an annual renewal. If you are considering any change to your current treatment plan, talk to your doctor first.
Educational, not medical advice. Migraine Tracker: CGRP Log is a personal tracking tool, not a medical device. It does not diagnose, treat, or provide medical advice. Always talk to your clinician.
CGRP monoclonal antibodies are large-molecule biologics given by injection or infusion, designed primarily for prevention. Gepants are small-molecule oral pills that can be used for acute treatment and, in some cases, prevention. Both target the CGRP pathway but do so in different ways and on different timescales.
Gepants migraine explained: how oral CGRP receptor blockers work, who they are for, and what questions to bring to your next neurology appointment.
Learn how do CGRP antibodies work migraine prevention by blocking a key pain molecule, and what that means for tracking your response and supporting renewal.
Get calcitonin gene-related peptide migraine explained clearly: what CGRP does during attacks, how it is targeted by modern treatments, and what to track.
